慢性淋巴性白血病市場:KOL的洞察

本報告提供全球慢性淋巴性白血病市場相關調查，市場概要，以及已通過核准治療方法，開發平台趨勢，未來預測等資訊。

目錄

摘要整理

現在及未來的治療流程

調查目的

布魯頓氏酪氨酸激酶(BTK)抑制劑/分解劑

• 已通過核准治療藥
  • Imbruvica (ibrutinib; AbbVie/Janssen)
  • Calquence (acalabrutinib; AstraZeneca)
  • Brukinsa (zanubrutinib; BeiGene)
• 開發平台治療藥
  • Jaypirca (pirtobrutinib; Lilly)
  • NX-2127 (Nurix Therapeutics)

Bcl-2抑制劑

• 已通過核准治療方法
  • Venclexta/Venclyxto(venetoclax;AbbVie/Roche)
• 開發平台治療藥
  • BGB-11417(BeiGene)及 lisaftoclax(APG-2575;Ascentage Pharma)

單株抗體

• 已通過核准治療藥
  • Gazyva/Gazyvaro(Obinutuzumab;Roche)

CAR T細胞療法

• 開發平台治療藥
  • Breyanzi(lisocabtagene maraleucel;Bristol Myers Squibb)
  • MB-106(Mustang Bio)

今後的治療趨勢

• 重要的洞察的摘要

附錄(5)

How do experts assess BeiGene's Brukinsa against AstraZeneca's Calquence? Why are KOLs unconvinced about the prospects for Calquence + venetoclax + obinutuzumab triple-combination therapy? What underpins KOL confidence that Eli Lilly's Jaypirca could change the treatment paradigm for patients with R/R CLL? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the Report Highlights slidedeck and KOL Bulletins via the attachments area.

Table of Contents

Executive summary (8)

Current and future treatment algorithm

Research objectives (2)

Bruton's tyrosine kinase (BTK) inhibitors/degraders (51)

• Approved drugs (31)
  • Imbruvica (ibrutinib; AbbVie/Janssen) (13)
  • Calquence (acalabrutinib; AstraZeneca) (10)
  • Brukinsa (zanubrutinib; BeiGene) (8)

• Pipeline drugs (20)
  • Jaypirca (pirtobrutinib; Lilly) (12)
  • NX-2127 (Nurix Therapeutics) (8)

Bcl-2 inhibitors (18)

• Approved therapies (10)
  • Venclexta/Venclyxto (venetoclax; AbbVie/Roche) (10)

• Pipeline drugs (8)
  • BGB-11417 (BeiGene) & lisaftoclax (APG-2575; Ascentage Pharma) (8)

Monoclonal antibodies (7)

• Approved drugs (7)
  • Gazyva/Gazyvaro (obinutuzumab; Roche) (7)

CAR T-cell therapies (16)

• Pipeline drugs (16)
  • Breyanzi (lisocabtagene maraleucel; Bristol Myers Squibb) (11)
  • MB-106 (Mustang Bio) (5)

Future treatment trends (7)

• Key insights summary (7)

Appendix (5)

• KOL details (5)
  • KOLs from North America (2)
  • KOLs from Europe (2)